Financials data is unavailable for this security.
View more
Year on year Solara Active Pharma Sciences Ltd 's revenues fell -10.73% from 14.44bn to 12.89bn. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from a loss of 221.80m to a larger loss of 5.67bn.
| Gross margin | 37.34% |
|---|---|
| Net profit margin | -43.17% |
| Operating margin | -28.08% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in INRView more
In 2024, Solara Active Pharma Sciences Ltd did not generate a significant amount of cash. However, the company earned 1.09bn from its operations for a Cash Flow Margin of 8.45%. In addition the company used 35.10m on investing activities and also paid 1.06bn in financing cash flows.
| Cash flow per share | -118.10 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, growth in earnings per share excluding extraordinary items dropped -2,458.12%.
| Div yield(5 year avg) | 0.19% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | -- |
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -2,116.73 |
More ▼
